Mark C. Enright

Corporate Officer/Principal bei Imperial College London

Health Technology

Consumer Services

Profil

Mark C.
Enright is a Professor at Imperial College London since 2007.
He previously worked as a Research Director at AmpliPhi Biosciences Corp.
and Biocontrol Ltd.
(United Kingdom).
He obtained a doctorate degree from the University of Aberdeen.

Aktive Positionen von Mark C. Enright

Unternehmen	Position	Beginn
Imperial College London	Corporate Officer/Principal	31.10.2011

Alle aktiven Positionen von Mark C. Enright

Ehemalige bekannte Positionen von Mark C. Enright

Unternehmen	Position	Ende
Biocontrol Ltd. (United Kingdom) Biocontrol Ltd. (United Kingdom) BiotechnologyHealth Technology Biocontrol Ltd. develops treatment to cure antibiotic resistant infections. The company was founded by David Harper on October 20, 1997 and is headquartered in Newbury, the United Kingdom.	Technik-/Wissenschafts-/F&E-Leiter	-
AmpliPhi Biosciences Corp. AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA.	Technik-/Wissenschafts-/F&E-Leiter	-

Sehen Sie sich die Erfahrung von Mark C. Enright im Detail an

Ausbildung von Mark C. Enright

University of Aberdeen

Doctorate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Mark C. Enright im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	2
AmpliPhi Biosciences Corp. AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA.	Health Technology
Biocontrol Ltd. (United Kingdom) Biocontrol Ltd. (United Kingdom) BiotechnologyHealth Technology Biocontrol Ltd. develops treatment to cure antibiotic resistant infections. The company was founded by David Harper on October 20, 1997 and is headquartered in Newbury, the United Kingdom.	Health Technology